News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,918 Results
Type
Article (42349)
Company Profile (294)
Press Release (673275)
Section
Business (210383)
Career Advice (2091)
Deals (36626)
Drug Delivery (106)
Drug Development (83021)
Employer Resources (175)
FDA (16552)
Job Trends (15398)
News (355925)
Policy (33884)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (6)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2590)
Accelerated approval (2)
Adcomms (21)
Allergies (84)
Alliances (51372)
ALS (87)
Alzheimer's disease (1374)
Antibody-drug conjugate (ADC) (116)
Approvals (16552)
Artificial intelligence (246)
Autoimmune disease (18)
Automation (14)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (188)
Bladder cancer (58)
Brain cancer (26)
Breast cancer (251)
Cancer (2038)
Cardiovascular disease (171)
Career advice (1749)
Career pathing (30)
CAR-T (141)
Cell therapy (401)
Cervical cancer (19)
Clinical research (67271)
Collaboration (786)
Compensation (460)
Complete response letters (25)
COVID-19 (2652)
CRISPR (41)
C-suite (217)
Cystic fibrosis (101)
Data (1977)
Decentralized trials (2)
Denatured (26)
Depression (41)
Diabetes (253)
Diagnostics (6418)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (115)
Drug pricing (107)
Drug shortages (28)
Duchenne muscular dystrophy (86)
Earnings (87905)
Editorial (33)
Employer branding (21)
Employer resources (149)
Events (114549)
Executive appointments (661)
FDA (17682)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (698)
Gene editing (103)
Generative AI (20)
Gene therapy (293)
GLP-1 (724)
Government (4502)
Grass and pollen (4)
Guidances (48)
Healthcare (18992)
Huntington's disease (23)
IgA nephropathy (23)
Immunology and inflammation (113)
Indications (27)
Infectious disease (2784)
Inflammatory bowel disease (135)
Inflation Reduction Act (8)
Influenza (47)
Intellectual property (89)
Interviews (322)
IPO (16762)
IRA (47)
Job creations (4057)
Job search strategy (1492)
Kidney cancer (9)
Labor market (34)
Layoffs (477)
Leadership (16)
Legal (8368)
Liver cancer (71)
Lung cancer (294)
Lymphoma (136)
Machine learning (4)
Management (59)
Manufacturing (280)
MASH (63)
Medical device (13407)
Medtech (13412)
Mergers & acquisitions (20333)
Metabolic disorders (654)
Multiple sclerosis (70)
NASH (17)
Neurodegenerative disease (84)
Neuropsychiatric disorders (26)
Neuroscience (1870)
NextGen: Class of 2025 (6637)
Non-profit (4524)
Northern California (2441)
Now hiring (37)
Obesity (354)
Opinion (226)
Ovarian cancer (73)
Pain (87)
Pancreatic cancer (77)
Parkinson's disease (135)
Partnered (20)
Patents (209)
Patient recruitment (94)
Peanut (49)
People (59071)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (20860)
Phase II (29600)
Phase III (22190)
Pipeline (1052)
Podcasts (75)
Policy (125)
Postmarket research (2654)
Preclinical (8840)
Press Release (68)
Prostate cancer (95)
Psychedelics (31)
Radiopharmaceuticals (249)
Rare diseases (374)
Real estate (6251)
Recruiting (67)
Regulatory (23003)
Reports (46)
Research institute (2367)
Resumes & cover letters (358)
Rett syndrome (3)
RNA editing (4)
RSV (39)
Schizophrenia (72)
Series A (123)
Series B (79)
Service/supplier (12)
Sickle cell disease (54)
Southern California (2116)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (29)
Startups (3721)
State (2)
Stomach cancer (14)
Supply chain (60)
The Weekly (47)
United States (21435)
Vaccines (677)
Venture capitalists (37)
Webinars (12)
Weight loss (241)
Women's health (33)
Worklife (15)
Date
Today (142)
Last 7 days (735)
Last 30 days (2816)
Last 365 days (34086)
2025 (8253)
2024 (35770)
2023 (40630)
2022 (51797)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33137)
2016 (32662)
2015 (38617)
2014 (32517)
2013 (27630)
2012 (29731)
2011 (30487)
2010 (28497)
Location
Africa (782)
Alabama (49)
Alaska (7)
Arizona (231)
Arkansas (14)
Asia (40591)
Australia (6503)
California (5573)
Canada (1883)
China (487)
Colorado (250)
Connecticut (257)
Delaware (131)
Europe (86540)
Florida (825)
Georgia (194)
Idaho (57)
Illinois (511)
India (24)
Indiana (299)
Iowa (9)
Japan (146)
Kansas (100)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (838)
Massachusetts (4236)
Michigan (211)
Minnesota (372)
Mississippi (2)
Missouri (77)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1600)
New Mexico (29)
New York (1604)
North Carolina (940)
North Dakota (7)
Northern California (2441)
Ohio (191)
Oklahoma (14)
Oregon (38)
Pennsylvania (1266)
Puerto Rico (9)
Rhode Island (26)
South America (1161)
South Carolina (18)
South Dakota (1)
Southern California (2116)
Tennessee (93)
Texas (836)
Utah (166)
Virginia (138)
Washington D.C. (57)
Washington State (519)
West Virginia (3)
Wisconsin (51)
715,918 Results for "merrimack pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Merrimack Pharmaceuticals, Inc. announced that the stockholders at a Special Meeting held overwhelmingly approved adopting a Plan of Dissolution.
May 10, 2024
·
6 min read
Deals
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024.
May 9, 2024
·
9 min read
Genetown
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
Merrimack Pharmaceuticals, Inc. announced that it has filed notice with NASDAQ of the Company’s intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution at the Special Meeting of Stockholders of Merrimack scheduled to be held on Friday, May 10, 2024.
April 30, 2024
·
10 min read
Genetown
Merrimack Reports Full Year 2023 Financial Results
Merrimack Pharmaceuticals, Inc. announced its full year 2023 financial results for the period ended December 31, 2023.
March 7, 2024
·
7 min read
Genetown
Merrimack Receives $225 Million Milestone Payment from Ipsen
Merrimack Pharmaceuticals, Inc. announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
March 27, 2024
·
9 min read
Business
Merrimack Reports Third Quarter 2023 Financial Results
Merrimack Pharmaceuticals, Inc. announced its third quarter 2023 financial results for the period ended September 30, 2023.
November 2, 2023
·
6 min read
Business
Merrimack Reports Second Quarter 2023 Financial Results
Merrimack Pharmaceuticals, Inc. announced its second quarter 2023 financial results for the period ended June 30, 2023.
August 3, 2023
·
9 min read
Policy
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
Merrimack Pharmaceuticals, Inc. reported that Ipsen, SA issued a press release announcing the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® plus 5 fluorouracil/leucovorin and oxaliplatin as a first-line treatment for people living with metastatic pancreatic ductal adenocarcinoma.
February 13, 2024
·
12 min read
Business
Merrimack Reports First Quarter 2023 Financial Results
Merrimack Pharmaceuticals, Inc. announced its first quarter 2023 financial results for the period ended March 31, 2023.
May 4, 2023
·
9 min read
Press Releases
Universe Pharmaceuticals INC Announces Share Consolidation
March 20, 2025
·
3 min read
1 of 71,592
Next